N-cyclopropylmethyl-N-propyl-4-(2,4,6-trimethylphenyl)-1-phthalazinamine | 209416-14-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: N-cyclopropylmethyl-N-propyl-4-(2,4,6-trimethylphenyl)-1-phthalazinamine
• 英文别名: N-(cyclopropylmethyl)-4-mesityl-N-propylphthalazin-1-amine；N-(cyclopropylmethyl)-N-propyl-4-(2,4,6-trimethylphenyl)phthalazin-1-amine
• CAS: 209416-14-8
• 化学式: C₂₄H₂₉N₃
• 分子量: 359.514
• InChiKey: CIIYHIPXIODBGI-UHFFFAOYSA-N

物化性质

• 沸点：
  503.6±45.0 °C(Predicted)
• 密度：
  1.108±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.9
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  29
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  1,4-二氯酞嗪 、 N-丙基环丙甲胺 在 potassium fluoride 作用下， 以 异丁酰胺 为溶剂， 生成 N-cyclopropylmethyl-N-propyl-4-(2,4,6-trimethylphenyl)-1-phthalazinamine
  参考文献：
  名称：

  [EN] 3-ARYL-5,6-DISUBSTITUTED PYRIDAZINES
  [FR] PYRIDAZINES 3-ARYL-5,6-DISUBSTITUEES

  摘要：

  公开号：

  WO2006004589A3

文献信息

• Isoquinolinamine and phthalazinamine derivatives: corticotropin-releasing factor receptor CRF1 specific ligands
  申请人：Neurogen Corporation

  公开号：US06353103B1

  公开（公告）日：2002-03-05

  Disclosed are compounds that are highly selective partial agonists or antagonists at human CRF1 receptors that are useful in the diagnosis and treatment of treating stress related disorders such as post traumatic stress disorder (PTSD) as well as depression, headache and anxiety. The compounds have the formula or the pharmaceutically acceptable salts thereof wherein Ar, R1, R2, R3, R4 and W are various organic and inorganic substituents.

  本文披露了一种在人类CRF1受体上高度选择性的部分激动剂或拮抗剂，可用于诊断和治疗与压力相关的疾病，如创伤后应激障碍（PTSD），以及抑郁症、头痛和焦虑症。这些化合物具有以下结构式： 或其药用可接受的盐，其中Ar、R1、R2、R3、R4和W为各种有机和无机取代基。
• Certain Isoquinolinamine and phthalazinamine derivatives; corticotropin-releasing factor receptor CRF1 specific ligands
  申请人：Neurogen Corporation.

  公开号：US20010036945A1

  公开（公告）日：2001-11-01

  Disclosed are compounds that are highly selective partial agonists or antagonists at human CRF 1 receptors that are useful in the diagnosis and treatment of treating stress related disorders such as post traumatic stress disorder (PTSD) as well as depression, headache and anxiety. The compounds have the formula 1 or the pharmaceutically acceptable salts thereof wherein Ar, R 1 , R 2 , R 3 , R 4 and W are various organic and inorganic substituents.

  本发明涉及高度选择性的部分激动剂或拮抗剂，用于人类CRF1受体的诊断和治疗，用于治疗与压力相关的疾病，如创伤后应激障碍（PTSD），以及抑郁症，头痛和焦虑症。该化合物的式子为1，或其药学上可接受的盐，其中Ar，R1，R2，R3，R4和W是各种有机和无机取代基。
• Isoquinolinamine and phthalazinamine derivatives which interact with CRF receptors
  申请人：Neurogen Corporation

  公开号：US06235752B1

  公开（公告）日：2001-05-22

  Disclosed are compounds that are highly selective partial agonists or antagonists of CRF1 receptors. The disclosed compounds are useful in the diagnosis and treatment of stress related disorders such as post traumatic stress disorder (PTSD) as well as depression, headache, and anxiety. The compounds are represented by the formula wherein R1, R2, R3, R4, and Ar represent various inorganic and organic substituents. Also disclosed are pharmaceutical compositions and methods of treating post traumatic stress disorder, depression, headache, and anxiety.

  本发明涉及高度选择性部分激动剂或拮抗剂的CRF1受体化合物。所披露的化合物可用于诊断和治疗与压力有关的疾病，如创伤后应激障碍（PTSD），以及抑郁症，头痛和焦虑症。该化合物由以下公式表示：其中R1，R2，R3，R4和Ar表示各种无机和有机取代基。还披露了制药组合物和治疗创伤后应激障碍，抑郁症，头痛和焦虑症的方法。
• Certain isoquinolinamine and phthalazinamine derivatives: corticotropin-releasing factor receptor CRF1 specific ligands
  申请人：Neurogen Corporation

  公开号：US06440969B2

  公开（公告）日：2002-08-27

  Disclosed are compounds that are highly selective partial agonists or antagonists at human CRF1 receptors that are useful in the diagnosis and treatment of treating stress related disorders such as post traumatic stress disorder (PTSD) as well as depression, headache and anxiety. The compounds have the formula or the pharmaceutically acceptable salts thereof wherein Ar, R1, R2, R3, R4 and W are various organic and inorganic substituents.

  本发明涉及一种高度选择性的部分激动剂或拮抗剂化合物，其在人类CRF1受体上非常有用，可用于诊断和治疗与压力有关的疾病，如创伤后应激障碍（PTSD），以及抑郁症、头痛和焦虑症。该化合物的公式为或其药学上可接受的盐，其中Ar、R1、R2、R3、R4和W是各种有机和无机取代基。
• 3-aryl-5,6-disubstituted pyridazines
  申请人：Yoon Taeyoung

  公开号：US20110160187A1

  公开（公告）日：2011-06-30

  The present invention provides compounds of Formula (I) or (II) salt form or prodrug thereof, wherein variables are defined herein, that are modulators of metalloproteases such as matrix metalloproteases (MMPs) and ADAMs. The compounds or compositions described herein can be used to treat diseases associated with metalloprotease activity including, for example, arthritis, cancer, cardiovascular disorders, skin disorders, inflammation or allergic conditions.

  本发明提供了公式（I）或（II）的化合物，盐形式或其前药，其中变量在此定义，该化合物是金属蛋白酶的调节剂，如基质金属蛋白酶（MMPs）和ADAMs。本文所述的化合物或组合物可用于治疗与金属蛋白酶活性相关的疾病，包括但不限于关节炎，癌症，心血管疾病，皮肤疾病，炎症或过敏症。